SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients...
• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4231 | -50.7192519779 | 0.8342 | 0.85 | 0.4111 | 338610 | 0.50897808 | CS |
4 | -0.3679 | -47.2272143774 | 0.779 | 1.04 | 0.4111 | 336795 | 0.83681705 | CS |
12 | -0.4879 | -54.2714126808 | 0.899 | 1.04 | 0.4111 | 166366 | 0.84130116 | CS |
26 | -0.5989 | -59.297029703 | 1.01 | 1.18 | 0.4111 | 259782 | 0.90475015 | CS |
52 | -0.5989 | -59.297029703 | 1.01 | 1.18 | 0.4111 | 259782 | 0.90475015 | CS |
156 | -0.5989 | -59.297029703 | 1.01 | 1.18 | 0.4111 | 259782 | 0.90475015 | CS |
260 | -0.5989 | -59.297029703 | 1.01 | 1.18 | 0.4111 | 259782 | 0.90475015 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.